GALT
Galectin Therapeutics IncCompany with tickers: GALT
CIK
1133416
CUSIP
363225202
Shares Outstanding
65,856,898
13F Activity (30d)
4 filings
3 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $4,077,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $2,231,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-4,077,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-5,046,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.08 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.08 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |